Oxford Biomedica (LON:OXB) Stock Crosses Below 200 Day Moving Average – Here’s Why

Oxford Biomedica plc (LON:OXB)’s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 663.38 and traded as low as GBX 544. Oxford Biomedica shares last traded at GBX 560, with a volume of 11,794,788 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on OXB shares. Jefferies Financial Group assumed coverage on shares of Oxford Biomedica in a research note on Monday, March 23rd. They set a “buy” rating and a GBX 827 price target on the stock. Stifel Nicolaus reiterated a “buy” rating and set a GBX 950 target price on shares of Oxford Biomedica in a report on Wednesday, March 11th. Finally, Deutsche Bank Aktiengesellschaft lifted their target price on shares of Oxford Biomedica from GBX 735 to GBX 800 and gave the company a “buy” rating in a report on Friday, January 9th. Six research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, Oxford Biomedica presently has a consensus rating of “Moderate Buy” and an average price target of GBX 687.

Oxford Biomedica Price Performance

The company has a current ratio of 2.20, a quick ratio of 1.67 and a debt-to-equity ratio of 116.74. The firm has a market cap of £676.88 million, a price-to-earnings ratio of -15.46 and a beta of 1.04. The stock has a 50-day moving average of GBX 708.55 and a 200-day moving average of GBX 663.38.

Oxford Biomedica (LON:OXB) last released its quarterly earnings data on Thursday, March 26th. The biopharmaceutical company reported GBX (26.92) earnings per share for the quarter. Oxford Biomedica had a negative return on equity of 48.56% and a negative net margin of 17.85%. As a group, sell-side analysts forecast that Oxford Biomedica plc will post -31.0799998 EPS for the current fiscal year.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.